Medical device maker Medtronic plans to separate its diabetes business into a stand-alone company, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. The new company, led by the head of Medtronic's diabetes division Que Dallara, will have around 8,000 employees and be based in Northridge, California, the report said. The separation is expected to be completed within 18 months, the paper added.